東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Chimeric antigen receptor T-cell the...

Lee, Daniel W.,

Linked to FindBook

Google Book

Amazon

博客來

Chimeric antigen receptor T-cell therapies for cancer = a practical guide /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Chimeric antigen receptor T-cell therapies for cancer/ edited by Daniel W. Lee, Nirali N. Shah.
Reminder of title:	a practical guide /
other author:	Lee, Daniel W.,
Published:	Amsterdam, Netherlands :Elsevier, : 2020.,
Description:	1 online resource (xi, 222 p.) :ill.(chiefly col.)
Notes:	Includes bibliographical references.
[NT 15003449]:	Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome --Special considerations for ICU management of patients receiving CAR therapy -- Neurotoxicities after CAR-T cell immunotherapy -- Hematologic and non-CRS toxicities -- Response assessment and post-CAR-T cell therapy management -- Relapse management and role for consolidative hematopoietic stem cell transplantation following CAR-T cell therapy -- Promising chimeric antigen receptors for non-B cell hematological malignancies, pediatric solid tumors, and carcinomas -- CAR T celltherapy for CNS malignancies -- CAR 2.0: the next generation of synthetic receptor-based cellular therapy for cancer.
Subject:	T cells - Receptors. -
Online resource:	https://www.sciencedirect.com/science/book/9780323661812
ISBN:	9780323755979 (electronic bk.)

Chimeric antigen receptor T-cell therapies for cancer = a practical guide /
Chimeric antigen receptor T-cell therapies for cancera practical guide /[electronic resource] :edited by Daniel W. Lee, Nirali N. Shah. - Amsterdam, Netherlands :Elsevier,2020. - 1 online resource (xi, 222 p.) :ill.(chiefly col.)

Includes bibliographical references.

Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome --Special considerations for ICU management of patients receiving CAR therapy -- Neurotoxicities after CAR-T cell immunotherapy -- Hematologic and non-CRS toxicities -- Response assessment and post-CAR-T cell therapy management -- Relapse management and role for consolidative hematopoietic stem cell transplantation following CAR-T cell therapy -- Promising chimeric antigen receptors for non-B cell hematological malignancies, pediatric solid tumors, and carcinomas -- CAR T celltherapy for CNS malignancies -- CAR 2.0: the next generation of synthetic receptor-based cellular therapy for cancer.

ISBN: 9780323755979 (electronic bk.)Subjects--Topical Terms:

895417
T cells
--Receptors.Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: QR185.8.T2

Dewey Class. No.: 571.9/66

National Library of Medicine Call No.: QW 574

Chimeric antigen receptor T-cell therapies for cancer = a practical guide /
LDR:01941cmm a2200277 a 4500 001 2246322
006 m o d
007 cr |||||||||||
008 211223s2021 ne a gob 000 0 eng d
020 $a 9780323755979 (electronic bk.)
020 $a 0323755976 (electronic bk.)
020 $a 9780323661812 (paperback)
020 $a 0323661815 (paperback)
035 $a (OCoLC)1131860574
035 $a on1131860574
040 $a OPELS $b eng $c OPELS $d MMU $d INM $d OCLCO $d USU $d YDX $d OCLCF $d UKMGB $d OCLCA $d UK7LJ $d OCLCA
041 0 $a eng
050 4 $a QR185.8.T2
060 4 $a QW 574
082 0 4 $a 571.9/66 $2 23
245 0 0 $a Chimeric antigen receptor T-cell therapies for cancer $h [electronic resource] : $b a practical guide / $c edited by Daniel W. Lee, Nirali N. Shah.
260 $a Amsterdam, Netherlands : $b Elsevier, $c 2020.
300 $a 1 online resource (xi, 222 p.) : $b ill.(chiefly col.)
500 $a Includes bibliographical references.
505 0 $a Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome --Special considerations for ICU management of patients receiving CAR therapy -- Neurotoxicities after CAR-T cell immunotherapy -- Hematologic and non-CRS toxicities -- Response assessment and post-CAR-T cell therapy management -- Relapse management and role for consolidative hematopoietic stem cell transplantation following CAR-T cell therapy -- Promising chimeric antigen receptors for non-B cell hematological malignancies, pediatric solid tumors, and carcinomas -- CAR T celltherapy for CNS malignancies -- CAR 2.0: the next generation of synthetic receptor-based cellular therapy for cancer.
588 $a Description based on online resource; title from electronic title page (ClinicalKey, viewed December 19, 2019).
650 0 $a T cells $x Receptors. $3 895417
650 0 $a Tumor antigens. $3 895264
650 1 2 $a Receptors, Chimeric Antigen $x therapeutic use. $3 3509678
650 1 2 $a Neoplasms $x therapy. $3 616080
650 2 2 $a Immunotherapy, Adoptive. $3 3509679
650 2 2 $a Receptors, Antigen, T-Cell. $3 3509680
650 2 2 $a Cell- and Tissue-Based Therapy. $3 3509681
655 0 $a Electronic books. $2 lcsh $3 542853
700 1 $a Lee, Daniel W., $e editor. $3 3509676
700 1 $a Shah, Nirali, $c MD, $e editor. $3 3509677
856 4 0 $u https://www.sciencedirect.com/science/book/9780323661812